Novo Nordisk Raises Outlook on Soaring U.S. Demand for Diabetes, Obesity Drugs
- Novo Nordisk raised sales and operating profit outlook
- Strong demand for Ozempic and Wegovy in the U.S. drove the outlook increase
- The Denmark-based drug giant updated its guidance
- Biotech stock was rising Friday following the raised outlook
- Novo cited soaring demand for its diabetes and obesity drugs
